Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines - PubMed (original) (raw)
Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines
J Beilin et al. J Mol Endocrinol. 2000 Aug.
Abstract
The action of androgens is essential for the development of benign prostatic hyperplasia and carcinoma of the prostate. The androgen receptor is a ligand-dependent nuclear transcription factor. The transcriptional activation domain of the androgen receptor gene contains a polymorphic CAG repeat sequence. A shorter CAG repeat sequence within the normal range has been reported to be associated with increased risk of prostate cancer and symptomatic benign prostatic hyperplasia. Here, we examine the in vitro transcriptional activity of the androgen receptor (AR) with different numbers of CAG repeats within the normal range in a number of different cell lines of prostatic (LNCaP, PC3) and non-prostatic (COS-1, MCF7) origin. We utilize a luciferase reporter driven by the rat probasin promoter (-286/+28) containing two androgen receptor binding sites. Transcriptional activation of the androgen responsive reporter was observed to be greater with the AR containing 15 vs 31 CAG repeats in COS-1 cells (123.2+/-16.6 vs 78.2+/-10.9, P value 0.01) and the well differentiated prostate cancer cell line LNCaP (103.4+/-17.7 vs 81.4+/-7.7, P value 0.045). No difference was observed in the poorly differentiated prostate cancer cell line, PC3 (106.9+/-21.9 vs 109. 6+/-21.4, P>0.5) or the breast cancer cell line MCF7 (120.4+/-39.4 vs 103.1+/-23.1, P value >0.5). Dose-response experiments with varying quantities of ligand (0.01, 0.1, 1 and 10 nM dihydrotestosterone) or AR cDNA did not demonstrate significant differences in transactivation of the androgen responsive reporter in PC3 cells by the different AR constructs. This suggests that the lack of influence of CAG number in this prostatic cell line is not related to dose of ligand or quantity of androgen receptor. Western immunoblot analysis of androgen receptor protein in transiently transfected COS-1 cells did not demonstrate a difference in the expression of the androgen receptor protein with different numbers of CAG repeats following incubation in the presence or absence of androgen. Gel shift assay did not demonstrate increased DNA binding by androgen receptor with a shorter CAG repeat sequence. These experiments using a relatively androgen- and prostate-specific reporter provide evidence for an inverse relationship between androgen receptor transcriptional activity and the number of CAG repeats in the transcriptional activation domain. The effect of CAG repeat number was cell specific suggesting the involvement of accessory factors expressed differentially between different cell lines.
Similar articles
- Differential transactivation by the androgen receptor in prostate cancer cells.
Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Snoek R, et al. Prostate. 1998 Sep 1;36(4):256-63. doi: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d. Prostate. 1998. PMID: 9719026 - Effect of a short CAG (glutamine) repeat on human androgen receptor function.
Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Ding D, et al. Prostate. 2004 Jan 1;58(1):23-32. doi: 10.1002/pros.10316. Prostate. 2004. PMID: 14673949 - The androgen receptor CAG repeat: a modifier of carcinogenesis?
Ferro P, Catalano MG, Dell'Eva R, Fortunati N, Pfeffer U. Ferro P, et al. Mol Cell Endocrinol. 2002 Jul 31;193(1-2):109-20. doi: 10.1016/s0303-7207(02)00104-1. Mol Cell Endocrinol. 2002. PMID: 12161010 Review. - Androgen receptor CAG repeats and prostate cancer.
Nelson KA, Witte JS. Nelson KA, et al. Am J Epidemiol. 2002 May 15;155(10):883-90. doi: 10.1093/aje/155.10.883. Am J Epidemiol. 2002. PMID: 11994226 Review.
Cited by
- The role of testosterone in men's health: is it time for a new approach?
Diokno AC. Diokno AC. Int Urol Nephrol. 2022 Nov;54(11):2767-2774. doi: 10.1007/s11255-022-03292-4. Epub 2022 Aug 1. Int Urol Nephrol. 2022. PMID: 35909146 Review. - Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
Verma S, Prajapati KS, Kushwaha PP, Shuaib M, Kumar Singh A, Kumar S, Gupta S. Verma S, et al. Cancer Drug Resist. 2020 Sep 17;3(4):742-761. doi: 10.20517/cdr.2020.45. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582225 Free PMC article. Review. - Klinefelter Bone Microarchitecture Evolution with Testosterone Replacement Therapy.
Piot A, Plotton I, Boutroy S, Bacchetta J, Ailloud S, Lejeune H, Chapurlat RD, Szulc P, Confavreux CB. Piot A, et al. Calcif Tissue Int. 2022 Jul;111(1):35-46. doi: 10.1007/s00223-022-00956-2. Epub 2022 Feb 13. Calcif Tissue Int. 2022. PMID: 35152305 - Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer.
Ratajczak W, Lubkowski M, Lubkowska A. Ratajczak W, et al. Int J Mol Sci. 2022 Jan 14;23(2):897. doi: 10.3390/ijms23020897. Int J Mol Sci. 2022. PMID: 35055079 Free PMC article. Review. - Precise CAG repeat contraction in a Huntington's Disease mouse model is enabled by gene editing with SpCas9-NG.
Oura S, Noda T, Morimura N, Hitoshi S, Nishimasu H, Nagai Y, Nureki O, Ikawa M. Oura S, et al. Commun Biol. 2021 Jun 23;4(1):771. doi: 10.1038/s42003-021-02304-w. Commun Biol. 2021. PMID: 34163001 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials